Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Lymphoma, Follicular 2 Urinary Bladder Neck Obstruction 1 Triple Negative Breast Neoplasms 1 Thrombocythemia, Essential 1 Squamous Cell Carcinoma of Head and Neck 1 Renal Insufficiency 1 Prostatic Neoplasms 1 Prostatic Hyperplasia 1 Primary Myelofibrosis 1 Polycythemia Vera 1 Polycystic Ovary Syndrome 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Ovarian Cancer Recurrent 1 Obesity 1 Neoplasms 1 Myeloproliferative Disorders 1 Multiple Endocrine Neoplasia Type 1 1 Lymphoma, B-Cell 1 Lung Neoplasms 1 Lower Urinary Tract Symptoms 1 Erectile Dysfunction 1 Dendritic Cell Sarcoma, Interdigitating 1 Colorectal Neoplasms 1 Breast Neoplasms 1

Interventions

pembrolizumab 185 Gemcitabine 170 Paclitaxel 152 Carboplatin 137 Bevacizumab 128 Surveys and Questionnaires 118 Cisplatin 115 Docetaxel 114 Blood Specimen Collection 110 Cyclophosphamide 109 Exercise 108 Nivolumab 98 Fluorouracil 90 Capecitabine 86 Dexamethasone 81 Radiotherapy 80 Irinotecan 74 Standard of Care 69 Pemetrexed 68 Oxaliplatin 68 Leucovorin 64 Drug Therapy 64 Cetuximab 60 Erlotinib Hydrochloride 56 Sorafenib 53 atezolizumab 52 Ipilimumab 51 Doxorubicin 50 trametinib 47 Interviews as Topic 47

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasms × mirabegron × Clear all

NCT05779514 2023-03-22

Effect of Mirabegron on Promoting Brown Adipose Tissue Activation

Zhejiang Provincial People's Hospital

Phase NA Unknown

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡